William Greene

William Greene, M.D.


Executive Partners

San Francisco Office

Dr. William (Bill) Greene currently serves as an MPM Advisor and CEO of Iconic Therapeutics, an MPM portfolio company, which is developing novel therapeutics for ophthalmologic diseases and cancer. Bill is an experienced biotechnology executive and investor in biopharmaceuticals and medical devices.

Bill’s board and investment experience includes Alnara (acquired by Eli Lilly), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (acquired by Actelion), Idun Pharmaceuticals (acquired by Pfizer) and Intercell AG (ICLL). In addition to investing and serving on corporate boards, Bill has filled roles on MPM portfolio companies including interim Vice President of Regulatory Affairs, and Chief Medical Officer.  Prior to joining MPM, Bill was at Genentech (acquired by Roche) where he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and regulatory affairs in several therapeutic areas across all phases of drug development from translational research through post-marketing studies. Among products whose clinical development he led or participated in are Lucentis, Avastin, and Raptiva.  Prior to Genentech, Bill was at Yale Medical School where he studied, taught, and performed clinical research in Internal Medicine and Diagnostic Radiology. He has also been an Assistant Clinical Professor of Medicine at the University of California, San Francisco and was an active member of the teaching staff at San Francisco General Hospital.

In addition to his work with MPM, Bill’s passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and was Chairman of the Board and head of the Investment Committee of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.

Bill received his M.D. from the University of California, San Francisco and has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He earned his B.A. degree from Wesleyan University.